Preview Mode Links will not work in preview mode

Jun 26, 2024

Featuring perspectives from Ms Jamie Carroll, Ms Kelly EH Goodwin, Dr Erika Hamilton and Dr Hope S Rugo, including the following topics:

  • Introduction (0:00)
  • Overview of Antibody-Drug Conjugates (ADCs); HER2-Targeted ADCs for Breast Cancer — T-DM1, Trastuzumab Deruxtecan (7:22)
  • The Incidence and Management of Interstitial Lung Disease with ADCs (34:05)
  • ADCs Targeting Other Signaling Pathways in Breast Cancer — Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan (49:02)
  • ADCs for Other Tumor Types and Toxicities Associated with ADCs (1:14:53)

NCPD information and select publications